title: Primary peritoneal cancer: study of 14 cases and comparison with epithelial ovarian cancer.
abstract: OBJECTIVE
  Primary peritoneal carcinoma (PPC) is histologically similar to ovarian serous carcinoma, but its biochemical features remain obscure. The authors investigated and compared clinical findings, treatments, and outcomes of patients with PPS and those with epithelial ovarian cancer (EOC) patients.
  
  
  METHODS
  The authors retrospectively reviewed data from 14 patients with PPC and 219 patients with EOC treated at the present hospital from January 2005 to December 2012, including demographic data, pathologic findings, treatments, and outcomes.
  
  
  RESULTS
  Patients with PPC were significantly older (62.6 ± 8.4 years) than those with EOC (56.3 ± 11.3 years) (p = 0.045). There was no significant difference in serum CA-125 levels. The five-year survival rates did not differ significantly between patients with PPC (61.1%) and those with EOC (60.3%; p = 0.78); nor between patients with PPC and those with Stage III serous EOC (43.8%; p = 0.40).
  
  
  CONCLUSIONS
  Treatment strategies for EOC applied to PPC apparently led to similar survival patterns among the two patient groups. Cytoreductive surgery combined with pre/postoperative platinum-containing chemotherapy may be effective for PPC patients.
authors: T
authors: T
authors: Fukuda
authors: K
authors: K
authors: Imai
authors: M
authors: M
authors: Yamauchi
authors: M
authors: M
authors: Teramae
authors: Y
authors: Y
authors: Hashiguchi
authors: T
authors: T
authors: Ichimura
authors: T
authors: T
authors: Yasui
authors: T
authors: T
authors: Sumi
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology* / Q000628:therapy; D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018394:CA-125 Antigen / Q000097:blood*; D016190:Carboplatin / Q000008:administration & dosage; D000077216:Carcinoma, Ovarian Epithelial; D017024:Chemotherapy, Adjuvant; D065426:Cytoreduction Surgical Procedures; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000097:blood / Q000473:pathology* / Q000628:therapy; D010051:Ovarian Neoplasms / Q000097:blood / Q000473:pathology* / Q000628:therapy; D017239:Paclitaxel / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000097:blood / Q000473:pathology* / Q000628:therapy; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D018394:CA-125 Antigen; D016190:Carboplatin; D017239:Paclitaxel